rev:January 10, 1997

HOME (index page)

Return (master antibody page)

Return  (cytokeratin data page)


CYTOKERATIN   ANTIBODIES  

(anti-Human and others as indicated)

RDI Divison of Fitzgerald Industries Intl  offers a wide line of  antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.


ANTI-CYTOKERATIN  TYPE II



PRODUCT CODE :RDI-CBL 216

CLONE: AE3

ISOTYPE: IgG1

SOURCE: Mouse ascitic fluid.

PURIFICATION METHOD: Ion exchange chromatography.


SPECIFICITY: The AE3 antibody shows broad species specificity cross-reacting with keratins of human, rabbit, mouse, rat, bovine and chick. It has been used for studying the immuno-localization of epidermal keratins, tissue distribution of keratins, various diseases of epidermis, oral mucosa and other epithelia, and epithelia development. AE3 and AE1 (CBL215) have also been used extensively, individually or mixed together, for distinguishing carcinoma from non- carcinoma. The AE3 monoclonal anti-keratin was prepared against human epidermal keratin. The AE3 antibody recognizes most of the acidic (Type II) keratins. This lot showed reactivity with human epidermal cell keratin of 86 and 58K and skin at 58, 65 and 67K in immunoblot. Immunofluorescence showed broad keratin reactivity of human epidermal cell, oesophagus and cornea.


APPLICATIONS: * The AE3 antibody recognizes most of the acidic (TypeII) keratins. Since each epithelium contains at least one basic keratin the antibody is broadly reactive and stains positively almost all epithelia and their neoplasms.

* Works well not only on unfixed frozen sections, but also on alcohol- or formalin-fixed, paraffin embedded tissues.

* Western blotting.


REFERENCES: · Battifora, H. et al. Cancer 64, 843 - 848 (1984)

                          · Eichner, R. et al. J. Cell. Biol. 98, 1388 - 1396 (1984)

                          · Shi, S.-R. et al. Am. J. Pathol. 117, 53 - 63 (1984).

                          · Spagnolo, D.V. et al. Am. J. Clin. Pathol. 84, 697 - 704 (1985)

                          · Sun, T.-T. et al. The Cancer Cell 1, 169 - 176 (1984)

                          · Sun, T.-T.,et al. J. Invest. Dermatol. 81, 109 - 115 (1983).

                          · Sun, T.-T.,et al. The New York Acad. Sci. 455, 307 - 329 (1985).

                          · Woodcock-Mitchell, J. et al. J. Cell. Biol. 95, 580 - 588 (1982)

                          · Weiss, R.A. et al. J. Cell Biol. 98, 1397 - 1406 (1984)

PRESENTATION: Each monoclonal is delivered in a sealed vial at a concentration of 1mg/ml (0.2ml) in phosphate buffered saline solution containing 10mM sodium azide. We recommend that each laboratory determine an optimum working titre for use in its particular application.

STORAGE: Purified monoclonal antibodies are generally stable for long periods at 4oC.  However repeated warming to room temperature and re-cooling may result in a loss  of activity and hence effective working titre. It is recommended that monoclonal  antibodies are aliquotted upon receipt and then stored at -200C. After thawing they      should then be used as a stock solution for up to 60 days. Dilute working solutions   are best prepared on the day ofuse.

For research use only. Not supplied for use in human diagnostic or therapeutic procedures


RDI Divison of Fitzgerald Industries Intl

34 Junction Square Drive

Concord MA 01742-3049

USA

phone (800) 370-2222 or (201) 584-7093

fax     (978) 371-2266

EMAIL:antibodies@fitzgerald-fii.com

RETURN(cytokeratin page)